Please assess the completion status of the following clinical trial:

Trial Title: Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient should fully know and understand the content of consent form, and the patient is willing and able to sign an informed consent form~* Chinese outpatients with confirmed T2DM~* Patients of ≥ 18, \< 80 years old~* Patients currently use metformin monotherapy ≥ 1500 mg/day or maximum tolerable dose and whose glucose levels are not adequately controlled~* HbA1c ≥ 7% and \< 12%~* New user\* linagliptin or acarbose as combination therapy with metformin ≥ 1500 mg/day or maximum tolerable dose \*New user defined as a T2DM patient initiating linagliptin or acarbose as an add-on therapy.~These are patients who are on metformin and whose glucose levels are not adequately controlled.~Exclusion Criteria:~* Type 2 diabetes mellitus patients who previously used any DPP-4 inhibitor/ GLP-1 receptor agonist at index date or any AGI at index date, are not eligible to participate. Also excluded are patients who currently using any glucose-lowering agent as monotherapy other than metformin.~* Patients with clinically significant acute major organ or systemic disease or other condition judged by the investigator that would create difficulty for the 24-week follow-up.~* Patients who participated in a clinical trial within 2 months prior to study enrolment date.~* Patients diagnosed with Type 1 diabetes mellitus, secondary diabetes or gestational diabetes.~* Current treatment with systemic steroids at time of informed consent or within 6 weeks prior to informed consent.~* Patients with known significant GI disease as judged by the study physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Linagliptin Initiators (Type: None): None
- Acarbose Initiators (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).